Search Results - "Blumenfeld, Andrew"

Correction to: Real‑World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review.

Authors: Blumenfeld, Andrew M. Mechtler, Laszlo Cook, Lisa et al.

Source: Pain & Therapy. Feb2025, Vol. 14 Issue 1, p441-444. 4p.

Real-World Retrospective Safety Analysis of OnabotulinumtoxinA for the Treatment of Patients with Chronic Migraine and Concomitant Therapeutic Indications.

Authors: Blumenfeld, Andrew M. Rhyne, Christopher Martinez, Kenneth et al.

Source: Pain & Therapy. Apr2026, Vol. 15 Issue 2, p535-553. 19p.

OnabotulinumtoxinA for the preventive treatment of episodic migraine: Results from the phase 3, multicenter randomized, double-blind, placebo-controlled phase of the PRECLUDE trial.

Authors: Pozo-Rosich, Patricia Blumenfeld, Andrew M. Lipton, Richard B. et al.

Source: Cephalalgia. Oct2025, Vol. 45 Issue 10, p1-16. 16p.

When should the effectiveness of a botulinum toxin A for chronic migraine be assessed in the face of newest International Headache Society recommendations?

Authors: Boczarska-Jedynak, Magdalena Blumenfeld, Andrew M.

Source: Cephalalgia. July2025, Vol. 45 Issue 7, p1-2. 2p.

Safety, tolerability, and efficacy of atogepant added to onabotulinumtoxinA for the preventive treatment of chronic migraine: A phase 3, multicenter, 24-week, open-label study.

Authors: Rothrock, John Najib, Umer Ailani, Jessica et al.

Source: Cephalalgia. Apr2026, Vol. 46 Issue 4, p1-12. 12p.

Real-World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review.

Authors: Blumenfeld, Andrew M. Mechtler, Laszlo Cook, Lisa et al.

Source: Pain & Therapy. Dec2024, Vol. 13 Issue 6, p1571-1587. 17p.

What Is Combination Treatment in Migraine? Moving Toward a Uniform Definition of a Familiar Principle.

Authors: Lipton, Richard B. Ailani, Jessica Blumenfeld, Andrew M.

Source: Neurology & Therapy. Dec2024, Vol. 13 Issue 6, p1535-1540. 6p.

OnabotulinumtoxinA treatment among diverse racial groups: Post hoc analysis of the phase 4 C hronic migraine O nabotulinu M toxinA P rolonged E fficacy open‐ L abel (COMPEL) trial.

Authors: Blumenfeld, Andrew M. Charleston, Larry Kuruvilla, Deena et al.

Source: Headache: The Journal of Head & Face Pain. May2026, Vol. 66 Issue 5, p1069-1080.

Long-Term Reductions in Headache Frequency, Severity, and Disability with Eptinezumab in Adults with Chronic Migraine: Results from the PREVAIL Trial.

Authors: Starling, Amaal J. Kudrow, David Kapur, Neha et al.

Source: Pain & Therapy. Jun2026, Vol. 15 Issue 3, p785-801. 17p.

Benefits of eptinezumab on patient-reported disease burden and health-related quality of life in adults with chronic migraine and medication-overuse headache: Results from the placebo-controlled RESOLUTION trial.

Authors: Tepper, Stewart J. Schytz, Henrik W. Jensen, Rigmor H. et al.

Source: Cephalalgia. May2026, Vol. 46 Issue 5, p1-15. 15p.

Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review.

Authors: Blumenfeld, Andrew M. Lipton, Richard B. Silberstein, Stephen et al.

Source: Neurology & Therapy. Oct2023, Vol. 12 Issue 5, p1533-1551. 19p.

Adjunctive treatment of chronic migraine using an oral dental device: overview and results of a randomized placebo-controlled crossover study.

Authors: Blumenfeld, Andrew M. Boyd, James P.

Source: BMC Neurology. 3/4/2022, Vol. 22 Issue 1, p1-9. 9p.

MTIS 2018 Author index.

Source: Cephalalgia. 2018 Supplement, Vol. 38, p116-122. 7p.

Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials.

Authors: Lipton, Richard B Blumenfeld, Andrew Jensen, Christopher M et al.

Source: Cephalalgia. Feb 2023, Vol. 43 Issue 2, p1-11. 11p.

Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab.

Authors: Blumenfeld, Andrew Ettrup, Anders Hirman, Joe et al.

Source: BMC Neurology. 7/8/2022, Vol. 22 Issue 1, p1-9. 9p.

Practical Insights on the Identification and Management of Patients with Chronic Migraine.

Authors: Blumenfeld, Andrew Dueland, Aud Nome Evers, Stefan et al.

Source: Pain & Therapy. Jun2022, Vol. 11 Issue 2, p447-457. 11p.

Cerebral Artery Vasoconstriction After Galcanezumab Loading Dose for Migraine Prevention: A Case Report.

Authors: Asawavichienjinda, Thanin Jittapiromsak, Nutchawan Blumenfeld, Andrew

Source: Pain & Therapy. Dec2024, Vol. 13 Issue 6, p1705-1712. 8p.

Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications.

Authors: Goadsby, Peter J Blumenfeld, Andrew M Lipton, Richard B et al.

Source: Cephalalgia. Apr2021, Vol. 41 Issue 5, p546-560. 15p.

Injection technique of the upper face with onabotulinumtoxinA in chronic migraine.

Authors: Boczarska‐Jedynak, Magdalena Blumenfeld, Andrew M.

Source: Headache: The Journal of Head & Face Pain. Jul2023, Vol. 63 Issue 7, p849-860. 12p.

Subjects: Skeletal muscle physiology, Migraine prevention, Prevention of chronic diseases, Migraine diagnosis, Botulinum toxin, Frontal lobe, Injections, Muscle relaxants, Dermatologic nursing, Migraine, Face, Treatment effectiveness, Plastic surgery nursing, Documentation, Antibiotic prophylaxis, Photography, Facial muscles

Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the TANDEM study.

Authors: Ailani, Jessica Lipton, Richard B. Blumenfeld, Andrew M. et al.

Source: Headache: The Journal of Head & Face Pain. Jun2025, Vol. 65 Issue 6, p1005-1014.